Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

By Rury R. Holman, K. I. Thorne, A. Farmer, M. Davies, Joanne F Keenan, S. Paul, J. Levy. New England Journal of Medicine, 2007

692 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015, background): “As an alternative, the statement mentioned that, in selected patients, simpler (but somewhat less flexible) premixed formulations of intermediate- and short/rapid-acting insulins in fixed ratios could also be considered [44].”
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 (2010, background): “0% have required large insulin doses, failed to achieve the targeted HbA1c goal and resulted in weight gain [13, 14].”
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014, background): “As an alternative, the statement mentioned that, in selected patients, simpler (but somewhat less flexible) premixed formulations of intermediate- and short/rapid-acting insulins in fixed ratios could also be considered [44].”